CV Sciences（0HRT）株式概要CVサイエンシズ社は、北米でハーブサプリメント、ヘンプベースのカンナビジオール（CBD）、植物性食品の開発、製造、マーケティング、販売を行っている。 詳細0HRT ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6報酬過去5年間の収益は年間56.6%増加しました。 リスク分析意味のある時価総額がありません ( $6M )株式の流動性は非常に低い キャッシュランウェイが1年未満である すべてのリスクチェックを見る0HRT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0330.7% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-20m55m2016201920222025202620282031Revenue US$8.6mEarnings US$839.1kAdvancedSet Fair ValueView all narrativesCV Sciences, Inc. 競合他社Potter & MooreSymbol: AIM:PAMMarket cap: UK£16.1mRevolution Beauty GroupSymbol: AIM:REVBMarket cap: UK£32.2mChill Brands GroupSymbol: LSE:CHLLMarket cap: UK£1.8mProvexisSymbol: AIM:PXSMarket cap: UK£24.6m価格と性能株価の高値、安値、推移の概要CV Sciences過去の株価現在の株価US$0.0352週高値US$0.04452週安値US$0.03ベータ0.451ヶ月の変化n/a3ヶ月変化n/a1年変化n/a3年間の変化-31.61%5年間の変化-92.56%IPOからの変化-95.08%最新ニュースBoard Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Bill McCorkle was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 13CV Sciences, Inc. to Report Q1, 2026 Results on May 14, 2026CV Sciences, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 14, 2026お知らせ • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2026CV Sciences, Inc., Annual General Meeting, Jun 02, 2026.お知らせ • Mar 25CV Sciences, Inc. to Report Q4, 2025 Results on Mar 26, 2026CV Sciences, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026Board Change • Jan 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Bill McCorkle was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 11CV Sciences, Inc. to Report Q3, 2025 Results on Nov 13, 2025CV Sciences, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025最新情報をもっと見るRecent updatesBoard Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Bill McCorkle was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 13CV Sciences, Inc. to Report Q1, 2026 Results on May 14, 2026CV Sciences, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 14, 2026お知らせ • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2026CV Sciences, Inc., Annual General Meeting, Jun 02, 2026.お知らせ • Mar 25CV Sciences, Inc. to Report Q4, 2025 Results on Mar 26, 2026CV Sciences, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026Board Change • Jan 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Bill McCorkle was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 11CV Sciences, Inc. to Report Q3, 2025 Results on Nov 13, 2025CV Sciences, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025お知らせ • Aug 09CV Sciences, Inc. to Report Q2, 2025 Results on Aug 13, 2025CV Sciences, Inc. announced that they will report Q2, 2025 results After-Market on Aug 13, 2025お知らせ • May 10CV Sciences, Inc. to Report Q1, 2025 Results on May 14, 2025CV Sciences, Inc. announced that they will report Q1, 2025 results After-Market on May 14, 2025お知らせ • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2025CV Sciences, Inc., Annual General Meeting, Jun 02, 2025.お知らせ • Feb 20CV Sciences, Inc. announced that it has received $1.2 million in fundingCV Sciences, Inc announced that it has issued a secured promissory note in the principal amount of $1,600,000 on February 20, 2025. The Note carries an original issuance discount of $400,000お知らせ • Nov 22CV Sciences, Inc. (OTCPK:CVSI) agreed to acquire Extract Labs, Inc. from Higher Love Wellness Company LLC and Craig Henderson for $2 million.CV Sciences, Inc. (OTCPK:CVSI) agreed to acquire Extract Labs, Inc. from Higher Love Wellness Company LLC and Craig Henderson for $2 million on November 15, 2024. The acquisition of Extract Labs involves an initial payment at closing, which includes a cash payment of $0.4 million, subject to certain holdbacks and adjustments, and the issuance of CV Sciences' common stock valued at $1 million, based on the 60-day volume weighted average price. Additionally, the sellers of Extract Labs may receive up to $0.6 million in extra shares of CV Sciences' common stock if specific revenue targets are met during the two 12-month periods following the closing date. The Acquisition is anticipated to close during the first quarter of 2025 and is subject to customary conditions.お知らせ • Nov 08CV Sciences, Inc. to Report Q3, 2024 Results on Nov 14, 2024CV Sciences, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 14, 2024お知らせ • Aug 27CV Sciences, Inc. Launches +PlusHLTHCV Sciences, Inc. announced the launch of +PlusHLTH, an all-new line of cannabinoid-free supplements delivering targeted formulations for optimized health, improved performance, and increased vitality. Rooted in rigorous science and fortified by clinically proven wellness ingredients, the new line is now available nationwide at select retailers and from the Company's website. +PlusHLTH™ offers supplements that naturally enhance focus, mood, energy levels, metabolism, and more. Free of cannabinoids, +PlusHLTH™'s collection of innovative supplements includes: Clarity: The ultimate cognitive enhancer, scientifically proven to support overall mental acuity, boosting focus and improving memory retention with a potent blend of DMAE, Huperzine A, Rhodiola, and Lion's Mane. Available in gummy format. Peace: Formulated to help one navigate life's occasional stresses with ease, harnessing the calming properties of Holy Basil, Lemon Balm, St. John's Wort, and L-Theanine to maximize tranquility and serenity and promote relaxation and emotional balance. Available in gummy format. ReShape: More than just a diet supplement; it's a holistic approach to promoting well-being by supporting metabolism, enhancing energy levels, and achieving weight management goals with carefully selected ingredients Berberine, OEA (oleoylethanolamide), and Cinnamon. +PlusHLTH™ adds to CV Sciences' expansive collection of health and wellness products curated to help individuals excel in their daily endeavors. Within the last year, the Company has expanded its line of +PlusCBD™ products for pets and launched a collection of +PlusCBD™ Reserve gummies.Reported Earnings • Aug 14Second quarter 2024 earnings released: US$0.003 loss per share (vs US$0.008 loss in 2Q 2023)Second quarter 2024 results: US$0.003 loss per share (improved from US$0.008 loss in 2Q 2023). Revenue: US$3.95m (flat on 2Q 2023). Net loss: US$584.0k (loss narrowed 55% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.お知らせ • Aug 07CV Sciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024CV Sciences, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 13, 2024お知らせ • Jun 08CV Sciences, Inc. Elects Bill Mccorkle as DirectorsCV Sciences, Inc. at its AGM held on June 3, 2024 approved the election of Bill McCorkle as directors.Reported Earnings • May 16First quarter 2024 earnings released: US$0.004 loss per share (vs US$0.038 profit in 1Q 2023)First quarter 2024 results: US$0.004 loss per share (down from US$0.038 profit in 1Q 2023). Revenue: US$4.00m (down 3.5% from 1Q 2023). Net loss: US$628.0k (down 111% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.お知らせ • May 10CV Sciences, Inc. to Report Q1, 2024 Results on May 14, 2024CV Sciences, Inc. announced that they will report Q1, 2024 results Pre-Market on May 14, 2024お知らせ • Apr 13CV Sciences, Inc., Annual General Meeting, Jun 03, 2024CV Sciences, Inc., Annual General Meeting, Jun 03, 2024, at 10:00 Pacific Standard Time. Agenda: To elect three directors to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified, subject to prior death, resignation or removal; to ratify the selection of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; to approve, on a non-binding advisory basis, named executive officer compensation; and to consider and act upon such other business as may properly be brought before the Meeting or any adjournments or postponement thereof by or at the direction of our Board of Directors.お知らせ • Mar 26CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet ChewsCV Sciences, Inc. announces its latest innovation and product launch: a premier CBD chew tailored for pets, +PlusCBD™ Pet Hip and Joint Health Chews and +PlusCBD™ Pet Calming Care Chews. +PlusCBD™Pet wellness treats are crafted with the utmost care and supported by extensive research, and are now further validated by a landmark safety study backed by the National Animal Supplement Council (NASC). NASC is the leading trade association advocating for the health and wellness of companion animals that are given health supplements by their owners. The latest additions to the +PlusCBD lineup are now available nationwide at select retailers and from website. The pet wellness industry has witnessed a growing demand for natural alternatives to support pets' overall well-being. In response to this need, +PlusCBD™Pet has developed a premium CBD chew with the mission of providing the higher quality ingredients and best-in-class health and nutrition for cherished family members - pets. These formulas utilize the therapeutic properties of cannabidiol (CBD) derived from organic hemp plants. Along with CBD, the chews incorporate a curated selection of antioxidants, anti-inflammatory agents, and vital supplements designed to enhance the well-being of loving companion. While one in five dogs deal with joint pain, +PlusCBD Pet Hip and Joint Health Chews pairs premium THC-free hemp extract with Glucosamine, Turmeric, Rosehips, and Ginger Root providing relief for pets grappling with age-related stiffness or discomfort from physical activity. Similarly, more than 70% of dogs exhibit at least one anxiety-related behavior or habit. The non-GMO, THC-free +PlusCBD Pet Calming Care Chew employs a vitamin-rich formula of Chamomile, L-Tryptophan, Ginger Root, and L-Theanine, offering respite from anxiety and stress triggered by various stimuli such as separation, loud noises, or environmental changes, fostering a sense of relaxation and well-being in the devoted pet. Each CBD chew undergoes rigorous testing by independent laboratories to ensure purity, potency, and compliance with NASC's stringent quality standards. With a THC-free formulation and non-psychoactive properties, the chews offer a safe and effective solution for pet owners seeking natural alternatives for their companions. +PlusCBD™ Pet Hip and Joint Health Chews and Pet Calming Care Chews are the first new offerings from CV Sciences in 2024. In 2023, the award-winning wellness brand introduced several product offerings designed to elevate the health and well-being of the human consumers, including +PlusCBD™ Reserve Collection Extra Gummies, +PlusCBD™ Reserve Collection Sleep Gummies, +PlusCBD™ Daily Balance THC-Free Gummies and Softgels and +PlusCBD™ Reserve Collection Softgels. The continued expansion of the Company's industry-leading product catalog amplifies its commitment to providing all users, both two-legged and four, with research-supported, plant-based health and wellness alternatives.お知らせ • Mar 22CV Sciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024CV Sciences, Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 28, 2024お知らせ • Dec 14CV Sciences, Inc. (OTCPK:CVSI) acquired Cultured Foods Sp. z.o.o for $0.535 million.CV Sciences, Inc. (OTCPK:CVSI) acquired Cultured Foods Sp. z.o.o for $0.535 million on December 7, 2023.CV Sciences, Inc. (OTCPK:CVSI) completed the acquisition of Cultured Foods Sp. z.o.o on December 7, 2023.お知らせ • Nov 10CV Sciences, Inc. to Report Q3, 2023 Results on Nov 14, 2023CV Sciences, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 14, 2023お知らせ • Sep 06CV Sciences, Inc. Launches Reserve Sleep GummiesCV Sciences, Inc. announced the launch of +PlusCBD™?Reserve Collection Sleep Gummies as the brand continues to expand into the sleep aid market. The +PlusCBD™? Reserve Collection product line is crafted with a proprietary blend of full-spectrum cannabinoids with rich and bold profiles, providing intense support when needed. +PlusCBD™? Reserve Sleep Gummies are the latest addition to the successful Reserve Collection, formulated for consumers that want a product specifically designed for better sleep. Reserve Sleep Gummies give consumers more out of their nightly sleep supplement with 25mg CBD, 2.5mg THC, 5mg CBN, and 3mg of melatonin per gummy. Reserve Sleep allows consumers to regulate their circadian rhythms naturally while avoiding habit-forming sleep aids. Like all +PlusCBD™? reserve products, Sleep Gummies feature a potent blend of naturally occurring CBD and THC for a broader, full-spectrum cannabinoid experience. Sleep Gummies are available in a natural blackberry flavor sweetened with organic cane sugar. In addition to Reserve Sleep Gummies, CV Sciences recently launched Daily Balance THC Free softgels in a 100mg dose. These softgels are formulated for consumers who need higher CBD concentration to achieve their wellness goals without the effects of THC. 100mg THC Free softgels are easy-to-swallow, vegan and contain a precise dose, backed by clinical research to support everyday health.Reported Earnings • Aug 16Second quarter 2023 earnings released: US$0.008 loss per share (vs US$0.026 loss in 2Q 2022)Second quarter 2023 results: US$0.008 loss per share (improved from US$0.026 loss in 2Q 2022). Revenue: US$3.97m (down 4.2% from 2Q 2022). Net loss: US$1.29m (loss narrowed 64% from 2Q 2022).お知らせ • Aug 03CV Sciences, Inc. to Report Q2, 2023 Results on Aug 14, 2023CV Sciences, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 14, 2023Reported Earnings • May 18First quarter 2023 earnings released: EPS: US$0.038 (vs US$0.019 loss in 1Q 2022)First quarter 2023 results: EPS: US$0.038 (up from US$0.019 loss in 1Q 2022). Revenue: US$4.15m (down 6.7% from 1Q 2022). Net income: US$5.71m (up US$7.92m from 1Q 2022).お知らせ • May 10CV Sciences, Inc. to Report Q1, 2023 Results on May 15, 2023CV Sciences, Inc. announced that they will report Q1, 2023 results at 9:30 AM, US Eastern Standard Time on May 15, 2023Reported Earnings • Mar 30Full year 2022 earnings released: US$0.066 loss per share (vs US$0.14 loss in FY 2021)Full year 2022 results: US$0.066 loss per share (improved from US$0.14 loss in FY 2021). Revenue: US$16.2m (down 19% from FY 2021). Net loss: US$9.13m (loss narrowed 41% from FY 2021).Board Change • Mar 06Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Bill McCorkle was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Feb 15Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Bill McCorkle was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 23Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Bill McCorkle was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 19CV Sciences, Inc. Launches 30-Count of Popular +PlusCBD Reserve Collection SoftgelsCV Sciences, Inc. announced the launch of their popular +PlusCBD Reserve Collection Softgels in a 30-count bottle. This new offering will be available on +PlusCBD's' website on January 19, 2023. +PlusCBD Reserve Collection Softgels initially launched in August 2022 as the newest edition to CV Sciences' popular Reserve Collection, available in 60-count bottles. Reserve Softgels elicit feelings of relief and calm for consumers that require intense support. Featuring a 10:1 ratio of CBD to THC (12.5mg CBD to 1.25mg THC), Reserve Softgels are crafted with a full spectrum of cannabinoids to meet consumers' need states with a manageable microdose. Now offering a 30-count bottle in addition to the 60-count bottle, Reserve Softgels' size options allow consumers to better personalize their intake routines at a lower price point of $37.99 USD. The +PlusCBD Reserve Collection features a variety of product form factors, including gummies and oils in different flavors and potency. Consumers find calm, comfort and relief in the +PlusCBD Reserve Collection.お知らせ • Nov 09CV Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022CV Sciences, Inc. announced that they will report Q3, 2022 results Pre-Market on Nov 14, 2022お知らせ • Oct 27CV Sciences, Inc. Appoints William McCorkle as DirectorOn October 21, 2022, the Board of Directors of CV Sciences, Inc. appointed William McCorkle as a director on the Company's Board of Directors (the Board"). Pursuant to the Company's Bylaws, Mr. McCorkle shall hold office until the next election of directors by the stockholders of the Company. Mr. McCorkle shall serve as a member of the Company's Nominations and Governance Committee and Compensation Committee, and shall serve as Chair of the Audit Committee. Mr. McCorkle is an operational executive with over 30 years of experience solving problems with innovative solutions. Mr. McCorkle is experienced in managing day-to-day operations of small to large companies across multiple industries. Mr. McCorkle has held a variety of senior financial executive positions including CFO and COO of ISCA Inc., CFO, COO & Co-Founder of StemImmune Inc., CFO and COO of Genelux Corporation, and CFO and COO of Proformance Apparel Group, LLC. Mr. McCorkle received a Bachelor of Science in Accountancy from Bentley University. Mr. McCorkle's financial expertise, as well as his independence, judgment and exceptional leadership experience makes him a valuable addition to the Board. There are no arrangements or understandings between Mr. McCorkle and any other person pursuant to which Mr. McCorkle was selected as a director of the Company.お知らせ • Sep 28CV Sciences, Inc. Announces Proposed Settlement of Shareholder LitigationCV Sciences, Inc. announced that CV Sciences has received preliminary approval of the proposed settlement of six shareholder derivative lawsuits pending in Nevada and California. These lawsuits alleged breach of fiduciary duty and other claims against current and former board members arising out of a tweet issued by Citron Research on August 20, 2018, suggesting that the Company misled investors by failing to disclose certain facts related to its efforts to secure patent protection for its product CVSI-007 from the United States Patent and Trademark Office ("USPTO"), which facts plaintiffs alleged made it less likely that the Company would obtain patent protection. Defendants at all times denied any wrongdoing. On May 19, 2020, the USPTO issued a patent pertaining to CVSI-007. The settlement agreement was executed by on July 28, 2022. On September 21, 2022, the District Court of Clark County, Nevada granted a motion for preliminary approval of the settlement agreement. On November 14, 2022, at 1:30 p.m., the District Court of Clark County, Nevada will hold a hearing to determine whether to grant final approval of the settlement agreement. The proposed settlement, if approved by the court, will resolve all claims asserted the defendants in these shareholder actions without any admission, concession or finding of any fault, liability or wrongdoing by the Company or any defendant. CV Sciences and the individual defendants continue to deny any wrongdoing. The proposed settlement contemplates the implementation by the Company of certain corporate reforms and payment of $275,000 in attorneys' fees to plaintiffs. The Company currently anticipates that all settlement payments will be paid through insurance, although no assurance can be provided.お知らせ • Aug 16CV Sciences, Inc. Announces Launch of PlusCBD Reserve Collection SoftgelsCV Sciences, Inc. announced the launch of +PlusCBD Reserve Collection Softgels to support stress relief and relaxation. The product will be available on +PlusCBD's' website on August 15, 2022. +PlusCBD Reserve Collection Softgels is the newest iteration of CV Sciences' top-selling Reserve Collection, the brand's sole THC line. Reserve Softgels are specially formulated to provide a full spectrum of cannabinoids, fostering feelings of calm and relief when consumers require intense support. Reserve Softgels feature a 10:1 ratio of CBD to THC (12.5mg CBD to 1.25mg THC), offering a manageable microdose perfect for consumers of all backgrounds and needs. +PlusCBD Reserve Collection Softgels are available in 60-count bottles. The Reserve Softgels join the +PlusCBD Reserve Collection's product lineup, featuring gummies and oils available in various flavors and potency. Rich and bold, the Reserve Collection elicits powerful feelings of calm, comfort and relief.お知らせ • Aug 10CV Sciences, Inc. to Report Q2, 2022 Results on Aug 15, 2022CV Sciences, Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 15, 2022お知らせ • Jul 28CV Sciences, Inc. Appoints Jamie Corroon as DirectorOn July 21, 2022, the Board of Directors of CV Sciences, Inc. appointed Dr. Jamie Corroon Jr., ND, MPH as a director on the Company's Board of Directors (the Board"). Pursuant to the Company's Bylaws, Dr. Corroon shall hold office until the next election of directors by the stockholders of the Company. From 2020-present, Dr. Corroon served on the Company's Medical Advisory Board. He is a licensed Naturopathic Doctor who advises dietary supplement and cannabis companies regarding science, regulation, and product development. Dr. Corroon is the founder of, and since 2017 has served as, the Medical Director and Principal Investigator for the Center for Medical Cannabis Education, a for-profit clinical practice and research entity. He also has served as a Research Investigator at the Helfgott Research Institute at the National University of Natural Medicine since 2017. Dr. Corroon received a Bachelor's Degree in Political Science from the University of Southern California and obtained a Master's Degree in Public Health, Epidemiology from San Diego State University. He received his Doctor of Naturopathic Medicine license from Bastyr University. Dr. Corroon is well published in peer-reviewed literature with recent publications that investigate the clinical and public health implications of the broadening acceptance of cannabis in society. Dr. Corroon's medical expertise, as well as his independence, judgment and exceptional leadership experience makes him a valuable addition to the Board.お知らせ • May 13CV Sciences, Inc. to Report Q1, 2022 Results on May 16, 2022CV Sciences, Inc. announced that they will report Q1, 2022 results Pre-Market on May 16, 2022お知らせ • Apr 16CV Sciences, Inc., Annual General Meeting, May 26, 2022CV Sciences, Inc., Annual General Meeting, May 26, 2022, at 10:00 Pacific Standard Time. Agenda: To elect two directors to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified, subject to prior death, resignation or removal; to approve an amendment to company's Certificate of Incorporation, as amended, to increase the number of shares of capital stock authorized for issuance thereunder from 200,000,000 shares to 800,000,000 shares, and the number of shares of common stock authorized for issuance thereunder from 190,000,000 shares to 790,000,000 shares;and to discuss other matters.お知らせ • Apr 03CV Sciences, Inc. announced delayed annual 10-K filingOn 04/01/2022, CV Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.Reported Earnings • Apr 02Full year 2021 earnings released: US$0.14 loss per share (vs US$0.22 loss in FY 2020)Full year 2021 results: US$0.14 loss per share (up from US$0.22 loss in FY 2020). Revenue: US$20.0m (down 18% from FY 2020). Net loss: US$15.6m (loss narrowed 30% from FY 2020). Over the next year, revenue is forecast to grow 20%, compared to a 6.9% growth forecast for the industry in the United Kingdom.お知らせ • Mar 29CV Sciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022CV Sciences, Inc. announced that they will report Q4, 2021 results After-Market on Mar 31, 2022お知らせ • Mar 10CV Sciences, Inc. Announces the Addition of +PlusCBD Relief Softgels to Its Wellness Line of CBD ProductsCV Sciences, Inc. announced the addition of +PlusCBD Relief Softgels to its Wellness line of CBD products, joining highly successful +PlusCBD Sleep & Calm Gummies. +PlusCBD Relief Softgels deliver seven times more CBDA and CBD than the original +PlusCBD raw formula and feature Levagen®+ PEA, the CBD-like compound shown by clinical studies to be an alternative to ibuprofen. This highly optimized trio promotes a healthy inflammatory response and provides a safe alternative in helping to manage occasional soreness.Buying Opportunity • Jan 15Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 6.6%. The fair value is estimated to be US$0.28, however is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 32% per annum over the last 3 years. The company became loss making over the last 3 years.お知らせ • Jan 12CV Sciences, Inc. Announces Launch of +PlusCBD Pain Relief TopicalsCV Sciences, Inc. announced the launch of +PlusCBD Pain Relief topicals: four unique Over-the-Counter products formulated to pinpoint sources of minor pain and aches using active ingredients including warming camphor and cooling menthol along with premium hemp-derived CBD and other natural emollients for skin-softening effects. The +PlusCBD Pain Relief Sport Recovery Stick is crafted for athletes and fitness enthusiasts that are active and on-the-go. This topical anti-inflammatory and analgesic stick is intended to provide temporary relief related to pain and inflammation while facilitating recovery from physical activity. The 1 oz Sport Recovery Stick is available in a convenient travel size for use on the go. Another topical analgesic cream, the +PlusCBD Pain Relief Penetrating Cream, is formulated to maximize the icy-heat effects of camphor and menthol, formulated with hemp-derived CBD, to alleviate occasional pain with sore muscles and aching joints. The +PlusCBD Pain Relief Muscle Cream can provide relief to individuals managing temporary muscle pain, stiffness or soreness related to tension, stress, overuse and other minor injuries. Finally, the +PlusCBD™ Pain Relief Arthritis Cream is formulated for arthritis patients, which represent over 22% of adults in the United States. The product’s ingredients specifically target the joints to relieve arthritis-related pain and discomfort.Reported Earnings • Aug 17Second quarter 2021 earnings released: US$0.033 loss per share (vs US$0.047 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: US$5.13m (down 5.0% from 2Q 2020). Net loss: US$3.53m (loss narrowed 25% from 2Q 2020).Board Change • Aug 17High number of new directorsIndependent Director Paul Blake was the last director to join the board, commencing their role in 2019.Reported Earnings • May 15First quarter 2021 earnings released: US$0.03 loss per share (vs US$0.052 loss in 1Q 2020)The company reported a soft first quarter result with weaker revenues and control over costs, although losses reduced. First quarter 2021 results: Revenue: US$4.84m (down 41% from 1Q 2020). Net loss: US$3.13m (loss narrowed 39% from 1Q 2020).お知らせ • May 12CV Sciences, Inc. Announces Launch of PlusCBD™ Calm and Sleep GummiesCV Sciences, Inc. announced the launch of PlusCBD™ Calm and Sleep: two flavorful gummies that support healthy stress responses and sleep cycles for people getting back to their normal routines. Each PlusCBD™ Calm gummy contains 10mg of CBD derived from sustainable hemp and two neurologically-active amino acids: 5-HTP and L-Theanine. Studies have shown that 5-HTP (5-hydroxytryptophan) is a direct precursor for synthesis of the neurotransmitter serotonin, which may facilitate calm feelings and a positive mood. L-Theanine is an amino acid found in green tea that has been extensively researched for stress management. The synergy between L-Theanine and 5-HTP, together with PlusCBD™ promotes a balanced brain chemistry, which may help consumers manage occasional anxiety that can result from life’s stressors. PlusCBD™ Sleep gummies also contain 10mg of CBD, in addition to active ingredients – including melatonin, magnolia bark and lemon balm, which work together to support a healthy circadian rhythm. Pre-clinical studies have shown that compounds found in magnolia bark extract may soothe nerves through the modulation of certain neurotransmitters, including GABA and also work with the endocannabinoid system to support relaxation. Lemon balm, which has been used as an herbal medicine around the world for decades, also contains active compounds that support the GABA neurotransmitter system, which studies have linked to promoting restful sleep. CV Sciences’ latest offerings are third-party tested and formulated by trusted experts to ensure each product contains meaningful amounts of active ingredients that are scientifically researched. PlusCBD™ Calm and Sleep gummies contain no artificial flavoring or sweeteners, making them an attractive option for those looking to support their stress response and sleep cycle without artificial additives. Both products will be available for purchase online at www.pluscbdoil.com/cbd-gummies-for-sleep-and-calm.html beginning May 11, 2021, and at retailers later this year.Reported Earnings • Mar 20Full year 2020 earnings released: US$0.22 loss per share (vs US$0.17 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$24.4m (down 55% from FY 2019). Net loss: US$22.3m (loss widened 34% from FY 2019).お知らせ • Mar 11CV Sciences, Inc. to Report Q4, 2020 Results on Mar 18, 2021CV Sciences, Inc. announced that they will report Q4, 2020 results After-Market on Mar 18, 2021株主還元0HRTGB Personal ProductsGB 市場7Dn/a1.3%2.5%1Yn/a-19.2%19.4%株主還元を見る業界別リターン: 0HRTがUK Personal Products業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: 0HRT UK市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is 0HRT's price volatile compared to industry and market?0HRT volatility0HRT Average Weekly Movementn/aPersonal Products Industry Average Movement5.1%Market Average Movement5.7%10% most volatile stocks in GB Market12.0%10% least volatile stocks in GB Market3.0%安定した株価: 0HRTの株価は、 UK市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間の0HRTのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト201043Joe Dowlingwww.cvsciences.comCVサイエンシズ社は、北米でハーブサプリメント、ヘンプベースのカンナビジオール（CBD）、植物性食品の開発、製造、マーケティング、販売を行っている。同社は、PlusCBD、PlusCBD Pet、PlusHLTH、Cultured Foods、Lunar Foxのブランド名で、栄養補助食品、ビューティーケア、特殊食品、ペット用品などのヘルスケア市場分野で、ウェブサイト、厳選された代理店、実店舗およびモルタル小売店、厳選された電子小売店を通じて製品を提供している。同社は以前はCannaVest Corp.として知られていたが、2016年1月にCV Sciences, Inc.に社名を変更した。CV Sciences, Inc.は2010年に法人化され、カリフォルニア州サンディエゴに本社を置いている。もっと見るCV Sciences, Inc. 基礎のまとめCV Sciences の収益と売上を時価総額と比較するとどうか。0HRT 基礎統計学時価総額US$6.01m収益（TTM）-US$1.49m売上高(TTM)US$13.38m0.4xP/Sレシオ-4.0xPER（株価収益率0HRT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0HRT 損益計算書（TTM）収益US$13.38m売上原価US$6.72m売上総利益US$6.66mその他の費用US$8.15m収益-US$1.49m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.0076グロス・マージン49.75%純利益率-11.15%有利子負債／自己資本比率80.6%0HRT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 19:23終値2026/05/19 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CV Sciences, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Pablo ZuanicCantor Fitzgerald & Co.Michael GrondahlNorthland Capital MarketsMichael LaveryPiper Sandler Companies2 その他のアナリストを表示
Board Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Bill McCorkle was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 13CV Sciences, Inc. to Report Q1, 2026 Results on May 14, 2026CV Sciences, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 14, 2026
お知らせ • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2026CV Sciences, Inc., Annual General Meeting, Jun 02, 2026.
お知らせ • Mar 25CV Sciences, Inc. to Report Q4, 2025 Results on Mar 26, 2026CV Sciences, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026
Board Change • Jan 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Bill McCorkle was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 11CV Sciences, Inc. to Report Q3, 2025 Results on Nov 13, 2025CV Sciences, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025
Board Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Bill McCorkle was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 13CV Sciences, Inc. to Report Q1, 2026 Results on May 14, 2026CV Sciences, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 14, 2026
お知らせ • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2026CV Sciences, Inc., Annual General Meeting, Jun 02, 2026.
お知らせ • Mar 25CV Sciences, Inc. to Report Q4, 2025 Results on Mar 26, 2026CV Sciences, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026
Board Change • Jan 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Bill McCorkle was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 11CV Sciences, Inc. to Report Q3, 2025 Results on Nov 13, 2025CV Sciences, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025
お知らせ • Aug 09CV Sciences, Inc. to Report Q2, 2025 Results on Aug 13, 2025CV Sciences, Inc. announced that they will report Q2, 2025 results After-Market on Aug 13, 2025
お知らせ • May 10CV Sciences, Inc. to Report Q1, 2025 Results on May 14, 2025CV Sciences, Inc. announced that they will report Q1, 2025 results After-Market on May 14, 2025
お知らせ • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2025CV Sciences, Inc., Annual General Meeting, Jun 02, 2025.
お知らせ • Feb 20CV Sciences, Inc. announced that it has received $1.2 million in fundingCV Sciences, Inc announced that it has issued a secured promissory note in the principal amount of $1,600,000 on February 20, 2025. The Note carries an original issuance discount of $400,000
お知らせ • Nov 22CV Sciences, Inc. (OTCPK:CVSI) agreed to acquire Extract Labs, Inc. from Higher Love Wellness Company LLC and Craig Henderson for $2 million.CV Sciences, Inc. (OTCPK:CVSI) agreed to acquire Extract Labs, Inc. from Higher Love Wellness Company LLC and Craig Henderson for $2 million on November 15, 2024. The acquisition of Extract Labs involves an initial payment at closing, which includes a cash payment of $0.4 million, subject to certain holdbacks and adjustments, and the issuance of CV Sciences' common stock valued at $1 million, based on the 60-day volume weighted average price. Additionally, the sellers of Extract Labs may receive up to $0.6 million in extra shares of CV Sciences' common stock if specific revenue targets are met during the two 12-month periods following the closing date. The Acquisition is anticipated to close during the first quarter of 2025 and is subject to customary conditions.
お知らせ • Nov 08CV Sciences, Inc. to Report Q3, 2024 Results on Nov 14, 2024CV Sciences, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 14, 2024
お知らせ • Aug 27CV Sciences, Inc. Launches +PlusHLTHCV Sciences, Inc. announced the launch of +PlusHLTH, an all-new line of cannabinoid-free supplements delivering targeted formulations for optimized health, improved performance, and increased vitality. Rooted in rigorous science and fortified by clinically proven wellness ingredients, the new line is now available nationwide at select retailers and from the Company's website. +PlusHLTH™ offers supplements that naturally enhance focus, mood, energy levels, metabolism, and more. Free of cannabinoids, +PlusHLTH™'s collection of innovative supplements includes: Clarity: The ultimate cognitive enhancer, scientifically proven to support overall mental acuity, boosting focus and improving memory retention with a potent blend of DMAE, Huperzine A, Rhodiola, and Lion's Mane. Available in gummy format. Peace: Formulated to help one navigate life's occasional stresses with ease, harnessing the calming properties of Holy Basil, Lemon Balm, St. John's Wort, and L-Theanine to maximize tranquility and serenity and promote relaxation and emotional balance. Available in gummy format. ReShape: More than just a diet supplement; it's a holistic approach to promoting well-being by supporting metabolism, enhancing energy levels, and achieving weight management goals with carefully selected ingredients Berberine, OEA (oleoylethanolamide), and Cinnamon. +PlusHLTH™ adds to CV Sciences' expansive collection of health and wellness products curated to help individuals excel in their daily endeavors. Within the last year, the Company has expanded its line of +PlusCBD™ products for pets and launched a collection of +PlusCBD™ Reserve gummies.
Reported Earnings • Aug 14Second quarter 2024 earnings released: US$0.003 loss per share (vs US$0.008 loss in 2Q 2023)Second quarter 2024 results: US$0.003 loss per share (improved from US$0.008 loss in 2Q 2023). Revenue: US$3.95m (flat on 2Q 2023). Net loss: US$584.0k (loss narrowed 55% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
お知らせ • Aug 07CV Sciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024CV Sciences, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 13, 2024
お知らせ • Jun 08CV Sciences, Inc. Elects Bill Mccorkle as DirectorsCV Sciences, Inc. at its AGM held on June 3, 2024 approved the election of Bill McCorkle as directors.
Reported Earnings • May 16First quarter 2024 earnings released: US$0.004 loss per share (vs US$0.038 profit in 1Q 2023)First quarter 2024 results: US$0.004 loss per share (down from US$0.038 profit in 1Q 2023). Revenue: US$4.00m (down 3.5% from 1Q 2023). Net loss: US$628.0k (down 111% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
お知らせ • May 10CV Sciences, Inc. to Report Q1, 2024 Results on May 14, 2024CV Sciences, Inc. announced that they will report Q1, 2024 results Pre-Market on May 14, 2024
お知らせ • Apr 13CV Sciences, Inc., Annual General Meeting, Jun 03, 2024CV Sciences, Inc., Annual General Meeting, Jun 03, 2024, at 10:00 Pacific Standard Time. Agenda: To elect three directors to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified, subject to prior death, resignation or removal; to ratify the selection of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; to approve, on a non-binding advisory basis, named executive officer compensation; and to consider and act upon such other business as may properly be brought before the Meeting or any adjournments or postponement thereof by or at the direction of our Board of Directors.
お知らせ • Mar 26CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet ChewsCV Sciences, Inc. announces its latest innovation and product launch: a premier CBD chew tailored for pets, +PlusCBD™ Pet Hip and Joint Health Chews and +PlusCBD™ Pet Calming Care Chews. +PlusCBD™Pet wellness treats are crafted with the utmost care and supported by extensive research, and are now further validated by a landmark safety study backed by the National Animal Supplement Council (NASC). NASC is the leading trade association advocating for the health and wellness of companion animals that are given health supplements by their owners. The latest additions to the +PlusCBD lineup are now available nationwide at select retailers and from website. The pet wellness industry has witnessed a growing demand for natural alternatives to support pets' overall well-being. In response to this need, +PlusCBD™Pet has developed a premium CBD chew with the mission of providing the higher quality ingredients and best-in-class health and nutrition for cherished family members - pets. These formulas utilize the therapeutic properties of cannabidiol (CBD) derived from organic hemp plants. Along with CBD, the chews incorporate a curated selection of antioxidants, anti-inflammatory agents, and vital supplements designed to enhance the well-being of loving companion. While one in five dogs deal with joint pain, +PlusCBD Pet Hip and Joint Health Chews pairs premium THC-free hemp extract with Glucosamine, Turmeric, Rosehips, and Ginger Root providing relief for pets grappling with age-related stiffness or discomfort from physical activity. Similarly, more than 70% of dogs exhibit at least one anxiety-related behavior or habit. The non-GMO, THC-free +PlusCBD Pet Calming Care Chew employs a vitamin-rich formula of Chamomile, L-Tryptophan, Ginger Root, and L-Theanine, offering respite from anxiety and stress triggered by various stimuli such as separation, loud noises, or environmental changes, fostering a sense of relaxation and well-being in the devoted pet. Each CBD chew undergoes rigorous testing by independent laboratories to ensure purity, potency, and compliance with NASC's stringent quality standards. With a THC-free formulation and non-psychoactive properties, the chews offer a safe and effective solution for pet owners seeking natural alternatives for their companions. +PlusCBD™ Pet Hip and Joint Health Chews and Pet Calming Care Chews are the first new offerings from CV Sciences in 2024. In 2023, the award-winning wellness brand introduced several product offerings designed to elevate the health and well-being of the human consumers, including +PlusCBD™ Reserve Collection Extra Gummies, +PlusCBD™ Reserve Collection Sleep Gummies, +PlusCBD™ Daily Balance THC-Free Gummies and Softgels and +PlusCBD™ Reserve Collection Softgels. The continued expansion of the Company's industry-leading product catalog amplifies its commitment to providing all users, both two-legged and four, with research-supported, plant-based health and wellness alternatives.
お知らせ • Mar 22CV Sciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024CV Sciences, Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 28, 2024
お知らせ • Dec 14CV Sciences, Inc. (OTCPK:CVSI) acquired Cultured Foods Sp. z.o.o for $0.535 million.CV Sciences, Inc. (OTCPK:CVSI) acquired Cultured Foods Sp. z.o.o for $0.535 million on December 7, 2023.CV Sciences, Inc. (OTCPK:CVSI) completed the acquisition of Cultured Foods Sp. z.o.o on December 7, 2023.
お知らせ • Nov 10CV Sciences, Inc. to Report Q3, 2023 Results on Nov 14, 2023CV Sciences, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 14, 2023
お知らせ • Sep 06CV Sciences, Inc. Launches Reserve Sleep GummiesCV Sciences, Inc. announced the launch of +PlusCBD™?Reserve Collection Sleep Gummies as the brand continues to expand into the sleep aid market. The +PlusCBD™? Reserve Collection product line is crafted with a proprietary blend of full-spectrum cannabinoids with rich and bold profiles, providing intense support when needed. +PlusCBD™? Reserve Sleep Gummies are the latest addition to the successful Reserve Collection, formulated for consumers that want a product specifically designed for better sleep. Reserve Sleep Gummies give consumers more out of their nightly sleep supplement with 25mg CBD, 2.5mg THC, 5mg CBN, and 3mg of melatonin per gummy. Reserve Sleep allows consumers to regulate their circadian rhythms naturally while avoiding habit-forming sleep aids. Like all +PlusCBD™? reserve products, Sleep Gummies feature a potent blend of naturally occurring CBD and THC for a broader, full-spectrum cannabinoid experience. Sleep Gummies are available in a natural blackberry flavor sweetened with organic cane sugar. In addition to Reserve Sleep Gummies, CV Sciences recently launched Daily Balance THC Free softgels in a 100mg dose. These softgels are formulated for consumers who need higher CBD concentration to achieve their wellness goals without the effects of THC. 100mg THC Free softgels are easy-to-swallow, vegan and contain a precise dose, backed by clinical research to support everyday health.
Reported Earnings • Aug 16Second quarter 2023 earnings released: US$0.008 loss per share (vs US$0.026 loss in 2Q 2022)Second quarter 2023 results: US$0.008 loss per share (improved from US$0.026 loss in 2Q 2022). Revenue: US$3.97m (down 4.2% from 2Q 2022). Net loss: US$1.29m (loss narrowed 64% from 2Q 2022).
お知らせ • Aug 03CV Sciences, Inc. to Report Q2, 2023 Results on Aug 14, 2023CV Sciences, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 14, 2023
Reported Earnings • May 18First quarter 2023 earnings released: EPS: US$0.038 (vs US$0.019 loss in 1Q 2022)First quarter 2023 results: EPS: US$0.038 (up from US$0.019 loss in 1Q 2022). Revenue: US$4.15m (down 6.7% from 1Q 2022). Net income: US$5.71m (up US$7.92m from 1Q 2022).
お知らせ • May 10CV Sciences, Inc. to Report Q1, 2023 Results on May 15, 2023CV Sciences, Inc. announced that they will report Q1, 2023 results at 9:30 AM, US Eastern Standard Time on May 15, 2023
Reported Earnings • Mar 30Full year 2022 earnings released: US$0.066 loss per share (vs US$0.14 loss in FY 2021)Full year 2022 results: US$0.066 loss per share (improved from US$0.14 loss in FY 2021). Revenue: US$16.2m (down 19% from FY 2021). Net loss: US$9.13m (loss narrowed 41% from FY 2021).
Board Change • Mar 06Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Bill McCorkle was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Feb 15Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Bill McCorkle was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 23Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Bill McCorkle was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 19CV Sciences, Inc. Launches 30-Count of Popular +PlusCBD Reserve Collection SoftgelsCV Sciences, Inc. announced the launch of their popular +PlusCBD Reserve Collection Softgels in a 30-count bottle. This new offering will be available on +PlusCBD's' website on January 19, 2023. +PlusCBD Reserve Collection Softgels initially launched in August 2022 as the newest edition to CV Sciences' popular Reserve Collection, available in 60-count bottles. Reserve Softgels elicit feelings of relief and calm for consumers that require intense support. Featuring a 10:1 ratio of CBD to THC (12.5mg CBD to 1.25mg THC), Reserve Softgels are crafted with a full spectrum of cannabinoids to meet consumers' need states with a manageable microdose. Now offering a 30-count bottle in addition to the 60-count bottle, Reserve Softgels' size options allow consumers to better personalize their intake routines at a lower price point of $37.99 USD. The +PlusCBD Reserve Collection features a variety of product form factors, including gummies and oils in different flavors and potency. Consumers find calm, comfort and relief in the +PlusCBD Reserve Collection.
お知らせ • Nov 09CV Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022CV Sciences, Inc. announced that they will report Q3, 2022 results Pre-Market on Nov 14, 2022
お知らせ • Oct 27CV Sciences, Inc. Appoints William McCorkle as DirectorOn October 21, 2022, the Board of Directors of CV Sciences, Inc. appointed William McCorkle as a director on the Company's Board of Directors (the Board"). Pursuant to the Company's Bylaws, Mr. McCorkle shall hold office until the next election of directors by the stockholders of the Company. Mr. McCorkle shall serve as a member of the Company's Nominations and Governance Committee and Compensation Committee, and shall serve as Chair of the Audit Committee. Mr. McCorkle is an operational executive with over 30 years of experience solving problems with innovative solutions. Mr. McCorkle is experienced in managing day-to-day operations of small to large companies across multiple industries. Mr. McCorkle has held a variety of senior financial executive positions including CFO and COO of ISCA Inc., CFO, COO & Co-Founder of StemImmune Inc., CFO and COO of Genelux Corporation, and CFO and COO of Proformance Apparel Group, LLC. Mr. McCorkle received a Bachelor of Science in Accountancy from Bentley University. Mr. McCorkle's financial expertise, as well as his independence, judgment and exceptional leadership experience makes him a valuable addition to the Board. There are no arrangements or understandings between Mr. McCorkle and any other person pursuant to which Mr. McCorkle was selected as a director of the Company.
お知らせ • Sep 28CV Sciences, Inc. Announces Proposed Settlement of Shareholder LitigationCV Sciences, Inc. announced that CV Sciences has received preliminary approval of the proposed settlement of six shareholder derivative lawsuits pending in Nevada and California. These lawsuits alleged breach of fiduciary duty and other claims against current and former board members arising out of a tweet issued by Citron Research on August 20, 2018, suggesting that the Company misled investors by failing to disclose certain facts related to its efforts to secure patent protection for its product CVSI-007 from the United States Patent and Trademark Office ("USPTO"), which facts plaintiffs alleged made it less likely that the Company would obtain patent protection. Defendants at all times denied any wrongdoing. On May 19, 2020, the USPTO issued a patent pertaining to CVSI-007. The settlement agreement was executed by on July 28, 2022. On September 21, 2022, the District Court of Clark County, Nevada granted a motion for preliminary approval of the settlement agreement. On November 14, 2022, at 1:30 p.m., the District Court of Clark County, Nevada will hold a hearing to determine whether to grant final approval of the settlement agreement. The proposed settlement, if approved by the court, will resolve all claims asserted the defendants in these shareholder actions without any admission, concession or finding of any fault, liability or wrongdoing by the Company or any defendant. CV Sciences and the individual defendants continue to deny any wrongdoing. The proposed settlement contemplates the implementation by the Company of certain corporate reforms and payment of $275,000 in attorneys' fees to plaintiffs. The Company currently anticipates that all settlement payments will be paid through insurance, although no assurance can be provided.
お知らせ • Aug 16CV Sciences, Inc. Announces Launch of PlusCBD Reserve Collection SoftgelsCV Sciences, Inc. announced the launch of +PlusCBD Reserve Collection Softgels to support stress relief and relaxation. The product will be available on +PlusCBD's' website on August 15, 2022. +PlusCBD Reserve Collection Softgels is the newest iteration of CV Sciences' top-selling Reserve Collection, the brand's sole THC line. Reserve Softgels are specially formulated to provide a full spectrum of cannabinoids, fostering feelings of calm and relief when consumers require intense support. Reserve Softgels feature a 10:1 ratio of CBD to THC (12.5mg CBD to 1.25mg THC), offering a manageable microdose perfect for consumers of all backgrounds and needs. +PlusCBD Reserve Collection Softgels are available in 60-count bottles. The Reserve Softgels join the +PlusCBD Reserve Collection's product lineup, featuring gummies and oils available in various flavors and potency. Rich and bold, the Reserve Collection elicits powerful feelings of calm, comfort and relief.
お知らせ • Aug 10CV Sciences, Inc. to Report Q2, 2022 Results on Aug 15, 2022CV Sciences, Inc. announced that they will report Q2, 2022 results Pre-Market on Aug 15, 2022
お知らせ • Jul 28CV Sciences, Inc. Appoints Jamie Corroon as DirectorOn July 21, 2022, the Board of Directors of CV Sciences, Inc. appointed Dr. Jamie Corroon Jr., ND, MPH as a director on the Company's Board of Directors (the Board"). Pursuant to the Company's Bylaws, Dr. Corroon shall hold office until the next election of directors by the stockholders of the Company. From 2020-present, Dr. Corroon served on the Company's Medical Advisory Board. He is a licensed Naturopathic Doctor who advises dietary supplement and cannabis companies regarding science, regulation, and product development. Dr. Corroon is the founder of, and since 2017 has served as, the Medical Director and Principal Investigator for the Center for Medical Cannabis Education, a for-profit clinical practice and research entity. He also has served as a Research Investigator at the Helfgott Research Institute at the National University of Natural Medicine since 2017. Dr. Corroon received a Bachelor's Degree in Political Science from the University of Southern California and obtained a Master's Degree in Public Health, Epidemiology from San Diego State University. He received his Doctor of Naturopathic Medicine license from Bastyr University. Dr. Corroon is well published in peer-reviewed literature with recent publications that investigate the clinical and public health implications of the broadening acceptance of cannabis in society. Dr. Corroon's medical expertise, as well as his independence, judgment and exceptional leadership experience makes him a valuable addition to the Board.
お知らせ • May 13CV Sciences, Inc. to Report Q1, 2022 Results on May 16, 2022CV Sciences, Inc. announced that they will report Q1, 2022 results Pre-Market on May 16, 2022
お知らせ • Apr 16CV Sciences, Inc., Annual General Meeting, May 26, 2022CV Sciences, Inc., Annual General Meeting, May 26, 2022, at 10:00 Pacific Standard Time. Agenda: To elect two directors to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified, subject to prior death, resignation or removal; to approve an amendment to company's Certificate of Incorporation, as amended, to increase the number of shares of capital stock authorized for issuance thereunder from 200,000,000 shares to 800,000,000 shares, and the number of shares of common stock authorized for issuance thereunder from 190,000,000 shares to 790,000,000 shares;and to discuss other matters.
お知らせ • Apr 03CV Sciences, Inc. announced delayed annual 10-K filingOn 04/01/2022, CV Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Reported Earnings • Apr 02Full year 2021 earnings released: US$0.14 loss per share (vs US$0.22 loss in FY 2020)Full year 2021 results: US$0.14 loss per share (up from US$0.22 loss in FY 2020). Revenue: US$20.0m (down 18% from FY 2020). Net loss: US$15.6m (loss narrowed 30% from FY 2020). Over the next year, revenue is forecast to grow 20%, compared to a 6.9% growth forecast for the industry in the United Kingdom.
お知らせ • Mar 29CV Sciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022CV Sciences, Inc. announced that they will report Q4, 2021 results After-Market on Mar 31, 2022
お知らせ • Mar 10CV Sciences, Inc. Announces the Addition of +PlusCBD Relief Softgels to Its Wellness Line of CBD ProductsCV Sciences, Inc. announced the addition of +PlusCBD Relief Softgels to its Wellness line of CBD products, joining highly successful +PlusCBD Sleep & Calm Gummies. +PlusCBD Relief Softgels deliver seven times more CBDA and CBD than the original +PlusCBD raw formula and feature Levagen®+ PEA, the CBD-like compound shown by clinical studies to be an alternative to ibuprofen. This highly optimized trio promotes a healthy inflammatory response and provides a safe alternative in helping to manage occasional soreness.
Buying Opportunity • Jan 15Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 6.6%. The fair value is estimated to be US$0.28, however is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 32% per annum over the last 3 years. The company became loss making over the last 3 years.
お知らせ • Jan 12CV Sciences, Inc. Announces Launch of +PlusCBD Pain Relief TopicalsCV Sciences, Inc. announced the launch of +PlusCBD Pain Relief topicals: four unique Over-the-Counter products formulated to pinpoint sources of minor pain and aches using active ingredients including warming camphor and cooling menthol along with premium hemp-derived CBD and other natural emollients for skin-softening effects. The +PlusCBD Pain Relief Sport Recovery Stick is crafted for athletes and fitness enthusiasts that are active and on-the-go. This topical anti-inflammatory and analgesic stick is intended to provide temporary relief related to pain and inflammation while facilitating recovery from physical activity. The 1 oz Sport Recovery Stick is available in a convenient travel size for use on the go. Another topical analgesic cream, the +PlusCBD Pain Relief Penetrating Cream, is formulated to maximize the icy-heat effects of camphor and menthol, formulated with hemp-derived CBD, to alleviate occasional pain with sore muscles and aching joints. The +PlusCBD Pain Relief Muscle Cream can provide relief to individuals managing temporary muscle pain, stiffness or soreness related to tension, stress, overuse and other minor injuries. Finally, the +PlusCBD™ Pain Relief Arthritis Cream is formulated for arthritis patients, which represent over 22% of adults in the United States. The product’s ingredients specifically target the joints to relieve arthritis-related pain and discomfort.
Reported Earnings • Aug 17Second quarter 2021 earnings released: US$0.033 loss per share (vs US$0.047 loss in 2Q 2020)The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: US$5.13m (down 5.0% from 2Q 2020). Net loss: US$3.53m (loss narrowed 25% from 2Q 2020).
Board Change • Aug 17High number of new directorsIndependent Director Paul Blake was the last director to join the board, commencing their role in 2019.
Reported Earnings • May 15First quarter 2021 earnings released: US$0.03 loss per share (vs US$0.052 loss in 1Q 2020)The company reported a soft first quarter result with weaker revenues and control over costs, although losses reduced. First quarter 2021 results: Revenue: US$4.84m (down 41% from 1Q 2020). Net loss: US$3.13m (loss narrowed 39% from 1Q 2020).
お知らせ • May 12CV Sciences, Inc. Announces Launch of PlusCBD™ Calm and Sleep GummiesCV Sciences, Inc. announced the launch of PlusCBD™ Calm and Sleep: two flavorful gummies that support healthy stress responses and sleep cycles for people getting back to their normal routines. Each PlusCBD™ Calm gummy contains 10mg of CBD derived from sustainable hemp and two neurologically-active amino acids: 5-HTP and L-Theanine. Studies have shown that 5-HTP (5-hydroxytryptophan) is a direct precursor for synthesis of the neurotransmitter serotonin, which may facilitate calm feelings and a positive mood. L-Theanine is an amino acid found in green tea that has been extensively researched for stress management. The synergy between L-Theanine and 5-HTP, together with PlusCBD™ promotes a balanced brain chemistry, which may help consumers manage occasional anxiety that can result from life’s stressors. PlusCBD™ Sleep gummies also contain 10mg of CBD, in addition to active ingredients – including melatonin, magnolia bark and lemon balm, which work together to support a healthy circadian rhythm. Pre-clinical studies have shown that compounds found in magnolia bark extract may soothe nerves through the modulation of certain neurotransmitters, including GABA and also work with the endocannabinoid system to support relaxation. Lemon balm, which has been used as an herbal medicine around the world for decades, also contains active compounds that support the GABA neurotransmitter system, which studies have linked to promoting restful sleep. CV Sciences’ latest offerings are third-party tested and formulated by trusted experts to ensure each product contains meaningful amounts of active ingredients that are scientifically researched. PlusCBD™ Calm and Sleep gummies contain no artificial flavoring or sweeteners, making them an attractive option for those looking to support their stress response and sleep cycle without artificial additives. Both products will be available for purchase online at www.pluscbdoil.com/cbd-gummies-for-sleep-and-calm.html beginning May 11, 2021, and at retailers later this year.
Reported Earnings • Mar 20Full year 2020 earnings released: US$0.22 loss per share (vs US$0.17 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: US$24.4m (down 55% from FY 2019). Net loss: US$22.3m (loss widened 34% from FY 2019).
お知らせ • Mar 11CV Sciences, Inc. to Report Q4, 2020 Results on Mar 18, 2021CV Sciences, Inc. announced that they will report Q4, 2020 results After-Market on Mar 18, 2021
